In_IN Vitro_NP Interaction_NP of_IN Caspofungin_NP Acetate_NP with_IN Voriconazole_NP against_IN Clinical_NP Isolates_NP of_IN Aspergillus_NP spp._NP The_DT interaction_NN between_IN caspofungin_NN acetate_NN and_CC voriconazole_NN was_VBD studied_VBN in_IN vitro_NN by_IN using_VBG 48_CD clinical_JJ Aspergillus_NP spp._NN isolates_NNS obtained_VBN from_IN patients_NNS with_IN invasive_JJ aspergillosis_NN ._SENT MICs_NNS were_VBD determined_VBN by_IN the_DT NCCLS_NP broth_NN microdilution_NN method_NN ._SENT Synergy_NN ,_, defined_VBN as_IN a_DT fractional_JJ inhibitory_JJ concentration_NN (_( FIC_NP )_) index_NN of_IN <1_JJ ,_, was_VBD detected_VBN in_IN 87.5_CD %_NN of_IN the_DT interactions_NNS ;_: an_DT additive_JJ effect_NN ,_, defined_VBN as_IN an_DT FIC_JJ index_NN of_IN 1.0_CD ,_, was_VBD observed_VBN in_IN 4.2_CD %_NN of_IN the_DT interactions_NNS ;_: and_CC a_DT subadditive_JJ effect_NN ,_, defined_VBN as_IN an_DT FIC_JJ index_NN of_IN 1.0_CD to_TO 2.0_CD ,_, was_VBD found_VBN in_IN 8.3_CD %_NN of_IN the_DT interactions_NNS ._SENT No_DT antagonism_NN was_VBD observed_VBN ._SENT Animal_JJ models_NNS are_VBP required_VBN to_TO validate_VB the_DT in_IN vivo_JJ significance_NN of_IN these_DT in_IN vitro_NN data_NNS presented_VBN for_IN the_DT combination_NN of_IN caspofungin_NN and_CC voriconazole_NN ._SENT Aspergillus_NN spp._NNS are_VBP common_JJ causes_NNS of_IN nosocomial_JJ pneumonia_NN and_CC disseminated_VBN infection_NN in_IN immunocompromised_JJ hosts_NNS such_JJ as_IN bone_NN marrow_NN transplant_NN recipients_NNS ,_, patients_NNS with_IN hematologic_JJ malignancies_NNS ,_, solid-organ_JJ transplant_NN recipients_NNS ,_, AIDS_NP patients_NNS ,_, and_CC patients_NNS with_IN pulmonary_JJ diseases_NNS ._SENT The_DT most_RBS common_JJ species_NNS include_VBP Aspergillus_NP fumigatus_NN (_( approximately_RB 90_CD %_NN of_IN the_DT cases_NNS )_) ,_, A._NP flavus_NN ,_, A._NP niger_NP ,_, A._NP terreus_NN ,_, and_CC A._NP nidulans_NNS ._SENT The_DT rate_NN of_IN mortality_NN from_IN invasive_JJ aspergillosis_NN remains_VBZ high_JJ in_IN severely_RB immunosuppressed_JJ patients_NNS who_WP receive_VBP standard_JJ antifungal_JJ treatment_NN with_IN amphotericin_NP B._NP Improved_NP responses_NNS have_VBP been_VBN observed_VBN in_IN less_JJR immunosuppressed_JJ patients_NNS sequentially_RB receiving_VBG amphotericin_NP B_NP followed_VBD by_IN itraconazole_NN and_CC those_DT receiving_VBG itraconazole_NN alone_RB ._SENT Nevertheless_RB ,_, these_DT drugs_NNS are_VBP not_RB always_RB effective_JJ or_CC tolerated_VBN in_IN severely_RB ill_JJ patients_NNS ,_, and_CC therefore_RB ,_, there_EX is_VBZ still_RB a_DT need_NN for_IN new_JJ therapies_NNS and_CC new_JJ approaches_NNS to_TO improve_VB the_DT outcome_NN of_IN this_DT disease_NN ._SENT The_DT echinocandin_NN caspofungin_NN acetate_NN (_( CAS_NP )_) ,_, formerly_RB MK-0991_JJ ,_, belongs_VBZ to_TO a_DT new_JJ class_NN of_IN antifungal_JJ drugs_NNS that_WDT inhibit_VBP the_DT synthesis_NN of_IN 1,3-beta-d-glucan_NP ,_, an_DT essential_JJ cell_NN wall_NN polysaccharide_NN that_WDT represents_VBZ a_DT selective_JJ target_NN present_NN only_RB in_IN fungal_JJ cell_NN walls_NNS ._SENT It_PP has_VBZ been_VBN shown_VBN to_TO have_VB in_IN vitro_NN and_CC in_IN vivo_JJ activities_NNS against_IN many_DT clinically_RB important_JJ fungi_NNS ,_, including_VBG Candida_NP and_CC Aspergillus_NP spp._NP ,_, and_CC has_VBZ recently_RB been_VBN approved_VBN for_IN the_DT treatment_NN of_IN refractory_JJ invasive_JJ aspergillosis_NN (_( -_: ,_, ,_, ;_: A._NP M._NP Flatery_NP ,_, P._NP Scott_NP Hicks_NP ,_, A._NP Wilcox_NP ,_, and_CC H._NP Rosen_NP ,_, Abstr_NP ._SENT 40th_JJ Intersci_NP ._SENT Conf_NP ._SENT Antimicrob_NN ._SENT Agents_NPS Chemother_NP ._SENT ,_, abstr_NN ._SENT 936_CD ,_, p._NN 369_CD ,_, 2000_CD )_) ._SENT Voriconazole_NP (_( VRC_NP )_) is_VBZ an_DT investigational_JJ triazole_NN antifungal_NN agent_NN that_WDT is_VBZ similar_JJ in_IN structure_NN and_CC spectrum_NN of_IN action_NN to_TO fluconazole_NN and_CC itraconazole_NN ,_, respectively_RB ._SENT This_DT agent_NN has_VBZ demonstrated_VBN substantial_JJ activity_NN in_IN both_CC in_IN vitro_NN and_CC in_IN vivo_JJ models_NNS against_IN a_DT variety_NN of_IN fungi_NNS such_JJ as_IN dimorphic_JJ fungi_NNS ,_, yeasts_NNS ,_, and_CC also_RB opportunistic_JJ filamentous_JJ fungi_NNS ,_, including_VBG Aspergillus_NP spp._NP ._SENT It_PP has_VBZ previously_RB been_VBN described_VBN that_IN combinations_NNS of_IN CAS_NP and_CC amphotericin_NP B_NP against_IN Candida_NP ,_, Cryptococcus_NP ,_, Aspergillus_NP ,_, and_CC Fusarium_NP have_VBP additive_JJ to_TO synergistic_JJ effects_NNS against_IN certain_JJ isolates_NNS ,_, with_IN no_DT evidence_NN of_IN antagonism_NN ._SENT In_IN the_DT case_NN of_IN VRC_NP ,_, the_DT combination_NN of_IN CAS_NN and_CC terbinafine_NN has_VBZ been_VBN shown_VBN to_TO have_VB synergistic_JJ activity_NN against_IN Aspergillus_NP sp_NN ._SENT ,_, Candida_NP albicans_NNS ,_, and_CC Candida_NP glabrata_NP isolates_VBZ (_( ,_, ;_: S._NP Perea_NP ,_, G._NP Gonzalez_NP ,_, A._NP W._NP Fothergill_NP ,_, D._NP A._NP Sutton_NP ,_, and_CC M._NP G._NP Rinaldi_NP ,_, Abstr_NP ._SENT 10th_JJ Annu_NP ._SENT Focus_VB Fungal_NP Infect_NNS ._SENT ,_, abstr_NN ._SENT 28_CD ,_, p._NN 69_CD ,_, 2000_CD )_) ._SENT The_DT aim_NN of_IN the_DT present_JJ study_NN was_VBD to_TO investigate_VB the_DT in_IN vitro_NN interaction_NN of_IN CAS_NP and_CC VRC_NP against_IN 48_CD isolates_NNS of_IN Aspergillus_NP spp._NP isolated_VBD from_IN patients_NNS with_IN invasive_JJ aspergillosis_NN ._SENT (_( This_DT work_NN was_VBD presented_VBN in_IN part_NN at_IN the_DT 101st_NP General_NP Meeting_VBG of_IN the_DT American_NP Society_NP for_IN Microbiology_NP ,_, Orlando_NP ,_, Fla._NP ,_, 2001_CD ._SENT )_) Forty-eight_NP isolates_VBZ of_IN Aspergillus_NP spp._NP (_( 24_CD A._NP fumigatus_NN ,_, 10_CD A._NP terreus_NN ,_, 9_CD A._NP flavus_NN ,_, and_CC 5_CD A._NP niger_NN isolates_NNS )_) were_VBD used_VBN throughout_IN the_DT study_NN ._SENT All_DT strains_NNS evaluated_VBN were_VBD clinical_JJ isolates_NNS submitted_VBN to_TO the_DT Fungus_NP Testing_NP Laboratory_NP ,_, University_NP of_IN Texas_NP Health_NP Science_NP Center_NP at_IN San_NP Antonio_NP ,_, from_IN patients_NNS with_IN invasive_JJ aspergillosis_NN ._SENT The_DT identities_NNS of_IN the_DT clinical_JJ isolates_NNS were_VBD confirmed_VBN by_IN standard_JJ microbiological_JJ procedures_NNS ,_, and_CC the_DT strains_NNS were_VBD stored_VBN in_IN sterile_JJ deionized_JJ water_NN at_IN room_NN temperature_NN until_IN they_PP were_VBD used_VBN in_IN the_DT study_NN ._SENT Paecilomyces_NP variotii_NP (_( UTHSC_NP 90-459_CD )_) was_VBD used_VBN as_IN the_DT control_NN organism_NN in_IN all_DT experiments_NNS ._SENT CAS_NP (_( Merck_NP ,_, Rahway_NP ,_, N.J._NP )_) and_CC VRC_NP (_( Pfizer_NP Inc._NP ,_, Sandwich_NP ,_, United_NP Kingdom_NP )_) were_VBD obtained_VBN in_IN reagent-grade_JJ powder_NN form_NN from_IN their_PP$ respective_JJ manufacturers_NNS ._SENT Stock_NN solutions_NNS were_VBD prepared_VBN in_IN water_NN (_( CAS_NN )_) and_CC polyethylene_NN glycol_NN 400_CD (_( VRC_NP )_) ._SENT Serial_JJ twofold_JJ dilutions_NNS of_IN each_DT antifungal_JJ agent_NN were_VBD prepared_VBN as_IN outlined_VBN in_IN document_NN M38-P_NN of_IN the_DT NCCLS_NP ._SENT Final_JJ dilutions_NNS were_VBD made_VBN in_IN antibiotic_JJ medium_NN 3_CD (_( M3_NP ;_: Difco_NP ,_, Detroit_NP ,_, Mich._NP )_) supplemented_VBD with_IN 2_CD %_NN glucose_NN (_( M3-2_JJ %_NN )_) ._SENT Drug_NN interactions_NNS were_VBD assessed_VBN by_IN a_DT checkerboard_NN microdilution_NN method_NN that_WDT also_RB included_VBD the_DT determination_NN of_IN the_DT MIC_NN of_IN each_DT drug_NN alone_RB by_IN using_VBG the_DT parameters_NNS outlined_VBN in_IN the_DT recommendations_NNS of_IN the_DT NCCLS_NP ._SENT The_DT final_JJ concentrations_NNS of_IN the_DT antifungal_JJ agents_NNS ranged_VBN from_IN 0.25_CD to_TO 64_CD mug/ml_NN for_IN CAS_NN and_CC 0.03_CD to_TO 4_CD mug/ml_NN for_IN VRC_NP ._SENT Inocula_NNS were_VBD prepared_VBN spectrophotometrically_RB and_CC further_RBR diluted_JJ in_IN order_NN to_TO obtain_VB final_JJ concentrations_NNS ranging_VBG from_IN 0.4_CD x_NN 104_CD to_TO 5_CD x_SYM 104_CD CFU/ml_NP ._SENT Each_DT microdilution_NN well_RB containing_VBG 100_CD mul_NN of_IN the_DT diluted_JJ (_( two_CD times_NNS )_) drug_NN concentrations_NNS of_IN both_DT antifungals_NNS (_( CAS_NP and_CC VRC_NP )_) was_VBD inoculated_VBN with_IN 100_CD mul_NN of_IN the_DT diluted_JJ (_( two_CD times_NNS )_) inoculum_NN suspension_NN (_( final_JJ volume_NN of_IN each_DT well_NN ,_, 200_CD mul_NN )_) ._SENT The_DT trays_NNS were_VBD incubated_VBN at_IN 35C_JJ ,_, and_CC the_DT results_NNS were_VBD read_VBN at_IN 48_CD h_NN visually_RB and_CC spectrophotometrically_RB with_IN a_DT spectrophotometric_JJ microtiter_NN plate_NN reader_NN (_( Dynex_NP Technologies_NPS Inc_NP ,_, Chantilly_JJ ,_, Va._NP )_) ._SENT MIC_JJ endpoints_NNS were_VBD determined_VBN as_IN the_DT first_JJ concentration_NN of_IN the_DT antifungal_JJ agent_NN ,_, either_CC alone_RB or_CC in_IN combination_NN ,_, at_IN which_WDT the_DT turbidity_NN in_IN the_DT well_NN was_VBD less_JJR than_IN 80_CD %_NN of_IN that_DT in_IN the_DT control_NN well_RB ._SENT The_DT geometric_JJ mean_NN (_( GM_NP )_) MICs_NP and_CC the_DT ranges_NNS of_IN MICs_NP were_VBD analyzed_VBN to_TO evaluate_VB the_DT in_IN vitro_NN activities_NNS of_IN both_DT drugs_NNS ,_, alone_RB and_CC in_IN combination_NN ._SENT Both_DT on-scale_NN and_CC off-scale_NN results_NNS were_VBD included_VBN in_IN the_DT analysis_NN ._SENT For_IN computation_NN of_IN the_DT GM_NP values_NNS ,_, high_JJ off-scale_NN MICs_NNS were_VBD converted_VBN to_TO the_DT twofold_JJ concentration_NN just_RB above_IN the_DT highest_JJS concentration_NN tested_VBD ._SENT When_WRB the_DT MIC_NN was_VBD off_RB the_DT bottom_NN of_IN the_DT scale_NN ,_, the_DT MIC_NP was_VBD assumed_VBN to_TO be_VB the_DT lowest_JJS MIC_NN tested_VBD ._SENT Drug_NN interactions_NNS were_VBD classified_VBN as_IN synergistic_JJ ,_, additive_JJ ,_, or_CC antagonistic_JJ on_IN the_DT basis_NN of_IN the_DT fractional_JJ inhibitory_JJ concentration_NN (_( FIC_NP )_) index_NN ._SENT The_DT FIC_JJ index_NN is_VBZ the_DT sum_NN of_IN the_DT FICs_NP of_IN each_DT of_IN the_DT drugs_NNS and_CC is_VBZ defined_VBN as_IN the_DT MIC_NN of_IN each_DT drug_NN when_WRB used_VBN in_IN combination_NN divided_VBN by_IN the_DT MIC_NN of_IN the_DT drug_NN when_WRB used_VBN alone_RB ._SENT The_DT interaction_NN was_VBD defined_VBN as_IN synergistic_JJ if_IN the_DT FIC_JJ index_NN was_VBD <1,_additive 2_CD ._SENT Synergy_NN was_VBD further_RBR subclassified_VBN as_IN marked_JJ (_( FIC_JJ index_NN ,_, <=0.50_NP )_) and_CC weak_JJ (_( FIC_JJ index_NN ,_, between_IN 0.50_CD and_CC 1.0_CD )_) ._SENT The_DT reductions_NNS in_IN the_DT GM_NP MICs_NP of_IN the_DT antifungals_NNS when_WRB they_PP were_VBD given_VBN in_IN combination_NN compared_VBN to_TO the_DT MICs_NN of_IN the_DT drugs_NNS when_WRB they_PP were_VBD given_VBN alone_RB were_VBD compared_VBN by_IN a_DT paired_VBN rank_NN test_NN ,_, a_DT nonparametric_JJ test_NN for_IN comparison_NN between_IN two_CD related_JJ samples_NNS ._SENT A_DT P_NN value_NN of_IN <0.05_NN was_VBD considered_VBN significant_JJ ._SENT The_DT MICs_NP of_IN CAS_NP for_IN the_DT 48_CD clinical_JJ Aspergillus_NP spp._NP isolates_NNS ranged_VBD from_IN <0.125_to 64_CD mug/ml_NN ,_, (_( GM_NP MIC_NP ,_, 30.2_CD mug/ml_NN ;_: MIC_JJ at_IN which_WDT 50_CD %_NN of_IN isolates_NNS are_VBP inhibited_VBN [_SYM MIC50_NP ]_SYM ,_, 32_CD mug/ml_NN ;_: MIC90_NP ,_, >64_NN mug/ml_NN )_) ._SENT There_EX were_VBD marked_JJ differences_NNS in_IN the_DT activities_NNS of_IN CAS_NN against_IN the_DT different_JJ species_NN ,_, with_IN A._NP flavus_NN being_VBG the_DT least_JJS susceptible_JJ (_( GM_NP CAS_NP MIC_NP ,_, 118.5_CD mug/ml_NN )_) and_CC A._NP niger_NP being_VBG the_DT most_RBS susceptible_JJ (_( GM_NP CAS_NP MIC_NP ,_, 1.3_CD mug/ml_NN )_) ._SENT VRC_NP MICs_NP ranged_VBD from_IN 0.125_CD to_TO 4_CD mug/ml_NN (_( GM_NP MIC_NP ,_, 0.66_CD mug/ml_NN ;_: MIC50_NP ,_, 0.5_CD mug/ml_NN ;_: MIC90_NP ,_, 1_CD mug/ml_NN )_) ._SENT The_DT MICs_NP determined_VBD spectrophotometrically_RB were_VBD similar_JJ to_TO the_DT MICs_NN determined_VBN visually_RB ._SENT The_DT MICs_NN calculated_VBN for_IN the_DT controls_NNS were_VBD within_IN the_DT acceptable_JJ ranges_NNS for_IN the_DT two_CD drugs_NNS tested_VBD ._SENT When_WRB given_VBN in_IN combination_NN ,_, significant_JJ reductions_NNS in_IN the_DT GM_NP CAS_NP MICs_NP (_( 30.2_CD to_TO 1.31_CD mug/ml_NN [_SYM P_NN <_SYM 0.001_CD ]_SYM )_) and_CC VRC_NP MICs_NP (_( 0.66_CD to_TO 0.16_CD mug/ml_NN [_SYM P_NN <_0.001]) 64_CD to_TO 0.5_CD and_CC 16_CD mug/ml_NN ,_, respectively_RB ,_, for_IN CAS_NN and_CC from_IN 0.5_CD and_CC 1_CD to_TO 0.25_CD and_CC 0.25_CD ,_, respectively_RB ,_, for_IN VRC_NP ._SENT Synergistic_JJ effects_NNS were_VBD observed_VBN in_IN 87.5_CD %_NN (_( 42_CD of_IN 48_CD )_) of_IN the_DT interactions_NNS ._SENT Of_IN those_DT ,_, 45.2_CD %_NN showed_VBD marked_JJ synergism_NN and_CC 54.8_CD %_NN showed_VBD weak_JJ synergism_NN ._SENT Additive_JJ effects_NNS were_VBD found_VBN in_IN 4.2_CD %_NN (_( 2_CD of_IN 48_CD )_) of_IN the_DT interactions_NNS ._SENT Subadditive_JJ effects_NNS were_VBD observed_VBN in_IN 8.3_CD %_NN (_( 4_CD of_IN 48_CD )_) of_IN the_DT interactions_NNS ._SENT No_DT antagonism_NN was_VBD observed_VBN ._SENT TABLE_NN 1_CD |_SYM Mode_NP of_IN interaction_NN between_IN CAS_NP and_CC VRC_NP against_IN 48_CD isolates_NNS of_IN Aspergillus_NP spp._NP We_PP have_VBP explored_VBN the_DT interaction_NN between_IN CAS_NN in_IN combination_NN with_IN the_DT new_JJ triazole_NN VRC_NN against_IN clinical_JJ Aspergillus_NP spp._NP isolates_VBZ from_IN patients_NNS with_IN invasive_JJ aspergillosis_NN ._SENT A_DT reproducible_JJ and_CC clinically_RB relevant_JJ method_NN for_IN susceptibility_NN testing_NN of_IN echinocandins_NNS has_VBZ not_RB been_VBN fully_RB established_VBN yet_RB ._SENT Different_JJ media_NNS (_( RPMI_NP ,_, M3_NP ,_, and_CC M3-2_NP %_NN )_) as_RB well_RB as_IN different_JJ MIC_JJ endpoints_NNS for_IN measuring_VBG the_DT in_IN vitro_NN activities_NNS of_IN these_DT new_JJ class_NN of_IN antifungals_NNS (_( MIC50_NP ,_, MIC80_NP ,_, MIC100_NP ,_, and_CC minimum_JJ effective_JJ concentration_NN )_) have_VBP been_VBN published_VBN previously_RB ._SENT Because_IN of_IN the_DT technical_JJ variability_NN ,_, data_NNS reported_VBD thus_RB far_RB on_IN the_DT activity_NN of_IN CAS_NP against_IN Aspergillus_NP show_VBP a_DT wide_JJ range_NN of_IN MICs_NP ._SENT Pfaller_NP et_FW al._FW used_VBN the_DT NCCLS_NP microdilution_NN methodology_NN and_CC reported_VBD MIC90s_NP after_IN 72_CD h_NN of_IN incubation_NN of_IN 0.12_CD mug/ml_NN ,_, using_VBG an_DT MIC_JJ endpoint_NN of_IN a_DT 75_CD %_NN reduction_NN in_IN growth_NN (_( MIC75_NP )_) ._SENT Del_FW Poeta_NP et_FW al._FW used_VBN the_DT macrodilution_NN methodology_NN proposed_VBN by_IN the_DT NCCLS_NP for_IN yeasts_NNS (_( M27-A_NP )_) ,_, an_DT inoculum_NN size_NN of_IN 0.5_CD x_NN 103_CD to_TO 2.5_CD x_SYM 103_CD CFU/ml_NN ,_, and_CC an_DT MIC80_NP endpoint_NN ._SENT The_DT GM_NP MICs_NP for_IN A._NP fumigatus_NP and_CC A._NP flavus_NN were_VBD <=0.09_and 64_CD ,_, <=0.03_NN ,_, and_CC 32_CD ,_, respectively_RB ._SENT With_IN respect_NN to_TO the_DT VRC_NP MICs_NP ,_, our_PP$ results_NNS are_VBP similar_JJ to_TO those_DT published_VBN recently_RB by_IN Espinel-Ingroff_NP when_WRB M3-2_JJ %_NN medium_NN ,_, reading_VBG of_IN the_DT MIC_JJ endpoint_NN as_IN MIC50_NP ,_, and_CC the_DT NCCLS_NP M38-P_NP methodology_NN were_VBD used_VBN ._SENT The_DT results_NNS obtained_VBN in_IN the_DT present_JJ study_NN with_IN a_DT combination_NN of_IN agents_NNS ,_, which_WDT showed_VBD either_DT synergy_NN or_CC additivity_NN but_CC no_DT evidence_NN of_IN antagonistic_JJ effects_NNS when_WRB both_DT agents_NNS were_VBD used_VBN in_IN combination_NN ,_, are_VBP very_RB encouraging_VBG ._SENT Although_IN the_DT exact_JJ mechanism_NN of_IN the_DT interaction_NN between_IN the_DT two_CD agents_NNS is_VBZ unknown_JJ ,_, one_CD theoretical_JJ explanation_NN for_IN such_PDT an_DT effect_NN would_MD be_VB the_DT simultaneous_JJ disruption_NN of_IN the_DT fungal_JJ cell_NN membrane_NN by_IN VRC_NP and_CC disruption_NN of_IN the_DT cell_NN wall_NN by_IN CAS_NN ,_, ultimately_RB decreasing_VBG the_DT cell_NN stability_NN and_CC leading_VBG to_TO the_DT death_NN of_IN the_DT fungal_JJ cell_NN ._SENT In_IN conclusion_NN ,_, our_PP$ results_NNS indicate_VBP that_IN a_DT combination_NN of_IN CAS_NP and_CC VRC_NP might_MD be_VB effective_JJ against_IN infections_NNS caused_VBN by_IN Aspergillus_NP spp._NP However_RB ,_, improvements_NNS to_TO the_DT methodology_NN used_VBN to_TO determine_VB the_DT in_IN vitro_NN susceptibility_NN of_IN the_DT fungi_NNS to_TO CAS_NNS ,_, as_RB well_RB as_IN in_IN vitro-in_NN vivo_JJ correlation_NN studies_NNS ,_, are_VBP required_VBN before_IN clinical_JJ studies_NNS can_MD be_VB conducted_VBN ._SENT 